journal
MENU ▼
Read by QxMD icon Read
search

Cancer Discovery

journal
https://www.readbyqxmd.com/read/30552152/mannose-inhibits-tumor-growth-and-increases-tumor-chemosensitivity
#1
(no author information available yet)
The monosaccharide mannose inhibits tumor glycolysis and enhances tumor response to chemotherapy.
December 14, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30552151/transcription-factor-motif-density-can-confer-transcriptional-addiction
#2
(no author information available yet)
ZFP64 binds to the MLL promoter and is essential for the growth of MLL -rearranged leukemia cells.
December 14, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30552150/the-e3-ligase-fbxo38-controls-pd-1-expression-and-antitumor-immunity
#3
(no author information available yet)
Regulation of PD-1 protein degradation by FBXO38 is necessary for T-cell antitumor activity.
December 14, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30552149/truxima-gets-high-marks-from-physicians
#4
(no author information available yet)
Doctors are convinced that Truxima, the first rituximab biosimilar approved by the FDA, is as effective as rituximab; European experience with the biosimilar over the last 2 years has also revealed no problems with unexpected side effects. However, cost will be a factor in determining whether doctors in the United States prescribe Truxima instead of rituximab.
December 14, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30541775/gsk-to-buy-tesaro-developer-of-niraparib
#5
(no author information available yet)
GlaxoSmithKline (GSK) has announced plans to buy Waltham, MA-based biotech Tesaro, maker of the once-daily oral PARP inhibitor niraparib (Zejula), in a deal valued at $5.1 billion.
December 12, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30541774/t-dm1-reduces-her2-breast-cancer-recurrence
#6
(no author information available yet)
Findings from the phase III KATHERINE trial show that patients with residual HER2+ breast cancer after neoadjuvant treatment are half as likely to develop invasive disease recurrence if they are treated with T-DM1 instead of trastuzumab, the current standard of care.
December 12, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30541773/ibrutinib-may-boost-efficacy-of-car-t-cells
#7
(no author information available yet)
Preliminary results from two studies indicate that concurrent treatment with ibrutinib may boost CAR T-cell therapy response rates among patients with relapsed/refractory CLL, while also minimizing the risk of severe cytokine release syndrome.
December 12, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30530733/first-line-ibrutinib-confirmed-for-cll
#8
(no author information available yet)
Ibrutinib should be a standard of care for many patients with chronic lymphocytic leukemia, according to results from two phase III trials. The BTK inhibitor, given alone or in combination with rituximab, improved clinical outcomes-including progression-free survival-when compared with chemoimmunotherapy regimens.
December 10, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30530743/swi-snf-mutations-confer-resistance-to-ibrutinib-plus-venetoclax-in-mcl
#9
(no author information available yet)
Biomarker analysis of a phase II trial reveals mechanisms of resistance to BTK and BCL2 inhibition.
December 7, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30530742/autophagy-sustains-tumors-by-maintaining-serum-arginine-levels
#10
(no author information available yet)
Impairment of host autophagy reduces circulating arginine and suppresses growth of some tumors.
December 7, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30530741/onecut2-is-a-key-node-and-therapeutic-target-in-lethal-prostate-cancer
#11
(no author information available yet)
The transcription factor ONECUT2 is a core regulator of metastatic castration-resistant prostate cancer.
December 7, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30523002/personalized-medicine-applied-to-aml
#12
(no author information available yet)
In the Beat AML Master Trial, researchers are genomically sequencing patients newly diagnosed with acute myeloid leukemia, and using the results to assign therapies. The approach, which has identified several promising treatments, demonstrates how personalized medicine can be applied in a clinical setting.
December 6, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30523001/augmenting-car-t-cells-with-pd-1-blockade
#13
(no author information available yet)
For patients with B-cell malignancies who experience poor initial responses to chimeric antigen receptor T-cell therapy, the addition of immune checkpoint blockade may prove beneficial, according to clinical reports presented at the 2018 American Society of Hematology Annual Meeting.
December 6, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30518523/a-phase-1b-dose-escalation-and-expansion-study-of-the-bcl-2-inhibitor-venetoclax-combined-with-tamoxifen-in-er-and-bcl-2-positive-metastatic-breast-cancer
#14
Geoffrey J Lindeman, Sheau Wen Lok, James R Whittle, Francois Vaillant, Charis E Teh, Louisa L Lo, Antonia N Policheni, Alice R T Bergin, Jayesh Desai, Sarah Ftouni, Luke C Gandolfo, Danny Liew, He K Liu, G Bruce Mann, Kate Moodie, Anand Murugasu, Bhupinder Pal, Andrew W Roberts, Mark A Rosenthal, Kylie Shackleton, Maria J Silva, Zhen R Siow, Gordon K Smyth, Leanne Taylor, Avraham Travers, Belinda Yeo, Miriam M Yeung, Andjelija Zivanovic Bujak, Sarah-Jane Dawson, Daniel H D Gray, Jane E Visvader
Venetoclax, a potent and selective BCL-2 inhibitor, synergizes with endocrine therapy in pre-clinical models of ER-positive breast cancer. Using a phase 1b 3+3 dose escalation and expansion study design, 33 patients with ER and BCL-2-positive metastatic disease (mean prior regimens, 2; range 0-8) were treated with daily tamoxifen (20 mg) and venetoclax (200-800 mg). Apart from uncomplicated 'on-target' lymphopenia, no dose-limiting toxicities or high-grade adverse events were observed in the escalation phase (15 patients), and 800 mg was selected as the recommended phase 2 dose (RP2D)...
December 5, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30514704/acquisition-of-the-recurrent-gly101val-mutation-in-bcl2-confers-resistance-to-venetoclax-in-patients-with-progressive-chronic-lymphocytic-leukemia
#15
Piers Blombery, Mary Ann Anderson, Jia-Nan Gong, Rachel Thijssen, Richard W Birkinshaw, Ella R Thompson, Charis E Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E Lew, Ian J Majewski, Daniel H D Gray, David A Westerman, Constantine S Tam, John F Seymour, Peter E Czabotar, David C S Huang, Andrew W Roberts
The BCL2 inhibitor, venetoclax, induces high rates of durable remission in patients with previously treated chronic lymphocytic leukemia (CLL). However, despite continuous daily treatment, leukemia recurs in most patients. To investigate the mechanisms of secondary resistance, we analyzed paired pre-venetoclax and progression samples from 15 patients with CLL progression enrolled on venetoclax clinical trials. The novel Gly101Val mutation in BCL2 was identified at progression in seven patients, but not at study entry...
December 4, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30514703/cancer-research-driven-by-patients-and-technology
#16
(no author information available yet)
The Count Me In initiative demonstrates how new technologies and approaches can be incorporated into large-scale, patient-driven research projects, an idea known as convergence. The initiative started with the Metastatic Breast Cancer Project, which has enrolled thousands of patients in an effort to generate a large, public database of clinical and genomic data.
December 4, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30510115/larotrectinib-ok-d-for-cancers-with-trk-fusions
#17
(no author information available yet)
Larotrectinib, a first-in-class TRK inhibitor, received accelerated approval for patients of all ages with solid tumors harboring NTRK fusions. It's the first tissue-agnostic marketing authorization for a targeted therapy and the first time a drug's initial approval has been site-independent.
December 3, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30504239/zw25-active-in-her2-positive-cancers
#18
(no author information available yet)
A novel anti-HER2 therapy, ZW25, may be effective and well tolerated in patients with a variety of HER2-positive cancers. In a phase I trial, patients treated with the drug-most of whom had gastroesophageal or colorectal cancer-had an objective response rate of 41% and mild side effects.
November 30, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30504238/jarid2-is-a-tumor-suppressor-in-myeloid-neoplasms
#19
(no author information available yet)
JARID2 recruits PRC2 to repress the self-renewal of multipotent progenitor cells.
November 30, 2018: Cancer Discovery
https://www.readbyqxmd.com/read/30504237/antiviral-and-antitumor-specific-t-cell-immunity-is-wdfy4-dependent
#20
(no author information available yet)
WDFY4 is required for classic dendritic cell-mediated cross-presentation of tumor and viral antigens.
November 30, 2018: Cancer Discovery
journal
journal
43599
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"